demonstrated that T‐DXd effectively reduces tumor growth and extends survival in PDX models of HER2‐positive, HER2‐low, and T‐DM1–resistant active breast cancer brain metastases (BCBM). This evidence concerns the gene ERBB2 and breast cancer.